Neurology

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa TrialOragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion StudySARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics,…

3 days ago
Plus Therapeutics Provides US Launch Update for its CNSide® DiagnosticPlus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private…

3 days ago
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s DiseaseAnavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43…

3 days ago
C8 Health Raises $12M Series A for the Healthcare Industry’s First AI-Powered, Best Practices Implementation PlatformC8 Health Raises $12M Series A for the Healthcare Industry’s First AI-Powered, Best Practices Implementation Platform

C8 Health Raises $12M Series A for the Healthcare Industry’s First AI-Powered, Best Practices Implementation Platform

The healthtech company is already addressing care inconsistency at over 100 hospitals in the United States NEW YORK, July 30,…

4 days ago
Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test SearchLabcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration…

4 days ago
Appendix 4C – Q4 FY25 Quarterly Cash Flow ReportAppendix 4C – Q4 FY25 Quarterly Cash Flow Report

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label…

4 days ago
Neu Health Launches in U.S., Supported by FDA Clearance for Parkinson’s Tremor MeasurementNeu Health Launches in U.S., Supported by FDA Clearance for Parkinson’s Tremor Measurement

Neu Health Launches in U.S., Supported by FDA Clearance for Parkinson’s Tremor Measurement

Delivering precision neurology via smartphone, Neu Health is built on the Oxford Discovery Cohort, one of the world's largest longitudinal…

5 days ago
Creyos Featured in Alzheimer’s Research at AAIC 2025Creyos Featured in Alzheimer’s Research at AAIC 2025

Creyos Featured in Alzheimer’s Research at AAIC 2025

Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital…

5 days ago
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s DiseaseTherini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs…

5 days ago
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company ProgressuniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA…

5 days ago